Hot Stock Alert:

(NASDAQ: ALBT)

Add This Stock to Your Watchlist Immediately — Here’s Why

Avalon GloboCare (NASDAQ: ALBT) is executing a transformation that includes a pending AI merger, a commercial FDA-cleared device, and a newly issued immunotherapy patent — all while trading below a $6M market cap with just 1.5M shares in the float.

logologologologologo

Latest News

Avalon GloboCare Advances Proposed Merger with YOOV with Filing of Registration StatementAvalon GloboCare Partners with SpecialtyHealth, Inc. to Power Police Chiefs’ Fitness Challenge with KetoAirAvalon GloboCare Announces Issuance of Patent for Novel CAR-T and CAR-NK Cell Technology in China

*Sponsored

Just 1.5M Shares in the Float — and a Real FDA Device in Use: Why ALBT May Be the Microcap to Watch

  • Ticker: NASDAQ: ALBT
  • Price: $2.55
  • Market Cap: ~$5.44 million
  • Float: 1.52 million shares
  • Shares Outstanding: 1.89 million
  • Reverse Split: 1-for-15 completed in 2024

A Microcap With Tangible Assets, Strategic IP, and a Diagnostic Platform Expanding in Real Time Avalon GloboCare (NASDAQ: ALBT) is one of the smallest companies listed on the Nasdaq by market cap — but it may also be one of the most overlooked. Behind its ~$5.44 million valuation lies a series of developments that point to real-world traction, intellectual property expansion, and product innovation.

Avalon is building a diagnostics-focused model anchored by precision consumer health technology and supported by cell therapy IP. It’s doing this with under 2 million shares outstanding — and just 1.52 million in the public float.

Insider ownership stands at approximately 57%. At current valuation levels, Avalon represents one of the tightest-capitalized structures on a U.S. exchange — but with assets already in market and partnerships in place.

Patent Issuance in Hong Kong for CAR-T and CAR-NK Platform

On July 15, 2025, Avalon announced that the Hong Kong Intellectual Property Department (HKIPD) has issued a new standard patent (Patent No. HK40074322) for the company’s bispecific CAR-T and CAR-NK cell platform. The 20-year patent is based on Chinese patent ZL202080015205.0 and is co-developed and co-owned with Avalon’s partner Arbele Limited, headquartered in Hong Kong.

The technology covered includes:

  • Bispecific anti-CD19xCD22 CAR design — intended to reduce tumor escape by targeting both antigens.
  • Localized cytokine induction — designed to activate immune response at tumor sites, potentially improving CAR cell performance and stimulating the patient’s immune system.

This patent builds on Avalon’s April patent issuance in China and extends protection through 2040 in the Hong Kong Special Administrative Region. It further strengthens Avalon’s global cell therapy IP portfolio and long-term commercialization optionality.

Commercial-Stage Medical Device Now in Use

On April 15, Avalon announced that its KetoAir™ handheld breathalyzer — a device designed to detect fat metabolism via acetone levels in breath — is being deployed by multiple state police departments as part of the BrAce 4 Impact Challenge, a public safety and wellness initiative. The device is actively marketed through Avalon’s commercial infrastructure and is owned and manufactured by its technology partner, Qi Diagnostics Limited.

Key Facts:

  • FDA-registered Class I medical device (Registration #3026284320)
  • Available now on the Apple App Store and Google Play
  • Integrated into real-time use within public sector health initiatives

This device moves Avalon beyond research and into the commercial arena, with verified use cases in law enforcement wellness programs.

Expanding the Platform: Cannabis Breathalyzer Now in Development

On June 26, 2025, Avalon entered into a definitive agreement with Qi Diagnostics to co-develop a cannabis breathalyzer, leveraging VOC (volatile organic compound) nanosensor technology. The collaboration includes Q&A Distribution, LLC, a subsidiary of Avalon.

The goal is to create a real-time, non-invasive point-of-care device capable of detecting potential cannabis impairment, with applications in roadside safety and workplace compliance. As legal cannabis usage expands, the gap in reliable impairment detection tools remains a public health challenge. Avalon’s entry into this space positions the company to address an unmet need with clear regulatory and commercial pathways.

This project marks a natural extension of Avalon’s diagnostic vision — broadening the use case of breath-based monitoring into one of the most policy-sensitive sectors in the country.

Patent Protection in China for Cell Therapy Platform

On April 10, Avalon announced the issuance of a patent in China (CN114502188 B) for its bispecific CAR-T and CAR-NK platform, developed in partnership with Arbele Limited. The IP protects a dual-targeting CAR system that addresses CD19 and CD22 antigens, combined with a localized cytokine release mechanism.

This patent grants 20 years of protection in China, a key global market for oncology innovation and biologics development.

The company’s cell therapy portfolio is not its primary commercial focus today, but the presence of protected intellectual property in this field provides longer-term strategic optionality and potential licensing value.

Structural Setup: Micro Float, High Insider Ownership

Avalon’s capital structure is extremely compact, with a combination of share scarcity and concentrated insider ownership.

  • 1.89 million shares outstanding
  • 1.52 million shares in the public float
  • 57% of shares held by insiders
  • Reverse split (1-for-15) completed in 2024

This type of equity setup is uncommon on the Nasdaq. Should material volume or investor interest increase, the supply-demand dynamics could shift rapidly — a scenario that has historically driven strong momentum in comparably structured microcap equities.

Bottom Line

Avalon GloboCare is building something atypical for its market cap: a commercialized medical device company with regulatory clearance, a pipeline expansion in a high-demand policy space (cannabis detection), and long-term patent value in the biotech space.

With a float of just 1.52 million shares, a sub-$6 million market cap, and multiple recent developments across diagnostics and IP, ALBT offers exposure to a diversified innovation pipeline within a Nasdaq-listed vehicle.

This is not a recommendation to buy or sell securities. It is a factual profile based on publicly disclosed developments. Investors are encouraged to review Avalon GloboCare’s filings and press releases, consult with a licensed financial advisor, and perform their own due diligence.

Avalon GloboCare Corp. (NASDAQ: ALBT)
  • Price: $2.55
  • Market Cap: ~$5.44 million
  • Float: 1.52 million shares
  • Key Assets: FDA-registered KetoAir™ breathalyzer, cannabis impairment detection device in development, CAR-T/NK patent in China

For those tracking microcaps with real product deployment and evolving pipelines, ALBT is a story worth watching.

STOCK INFORMATION

neov

Avalon GloboCare Corp.

ALBT neov Nasdaq Stock Market

February 26

Upcoming Earnings

EPS

Market cap

USD (%)

Market Closed (as of 06:29 GMT+5:30)

Add ALBT to your watchlist today

Disclaimer

This article is a paid advertisement and is for informational purposes only. It does not constitute investment advice, a solicitation, or an offer to buy or sell any securities. All information presented has been compiled from publicly available sources believed to be accurate as of the date of writing. However, no representation or warranty is made as to its accuracy or completeness.

This communication includes forward-looking statements, which involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Such statements reflect current expectations but are subject to change without notice.

Investors are strongly encouraged to conduct their own due diligence and consult with a licensed financial advisor before making any investment decisions.

For details regarding compensation and potential conflicts of interest, please refer to the full disclaimer below.

3333

― Join StockVerse Alerts Today!

Winning Stock Picks Sent To Inbox

Sign up for our newsletter to receive the latest updates, insights, and exclusive Winning Stock Picks. As of 2024, our alerts are up a total of 873.22%.

american-flagUSA

1309 coffeen ave suite 1200

sheridan wyoming 84403
www.stockverse.com

Inquiries

support@stockverse.com

— Follow Us

MASTER LEGAL DISCLAIMER

Effective Date: August 2024

Last Updated: June 15, 2025

Publisher: Relqo Media LLC (Wyoming, United States)

Subject Company: Avalon GloboCare Corp. (ALBT)

IMPORTANT SUMMARY — PLEASE READ FIRST

This website and any affiliated digital materials are published by Relqo Media LLC, a Wyoming marketing agency that has been compensated in cash by YachtXotics Enterprises Inc. to produce and distribute promotional content regarding Avalon GloboCare Corp. (NASDAQ: ALBT). This communication is a paid advertisement, not a research report, not investment advice, and not an independent publication. Relqo Media is not a broker-dealer, investment adviser, or securities analyst. Investing in small-cap or microcap securities is extremely speculative and may result in the total loss of your investment. We strongly urge all viewers to consult a licensed investment professional and perform their own due diligence.

1. NATURE AND INTENT OF THIS COMMUNICATION

Relqo Media LLC is a for-profit marketing agency engaged in paid promotions of public companies. The content we produce is strictly commercial and intended to create temporary public awareness, visibility, and short-term market activity around the featured company. This material is not impartial. All readers should interpret our content as a paid commercial advertisement and not as an editorial, research article, or independent commentary. We create advertisements, not analysis. These communications are not intended to be factual evaluations of the company’s operations or investment merit.

2. COMPENSATION FOR Avalon GloboCare Corp. (ALBT)

Relqo Media LLC has been contracted by YachtXotics Enterprises Inc. to conduct digital investor awareness and marketing campaigns on behalf of Avalon GloboCare Corp. (NASDAQ: ALBT). This agreement includes monetary compensation in exchange for producing and disseminating promotional content across various media platforms.

As of June 25, 2025, Relqo Media LLC has received and will continue to receive compensation for its services as follows:

  • $14,200 for a campaign running from June 25, 2025, through June 26, 2025.
  • $10,000 for a subsequent campaign conducted from July 13, 2025, through July 14, 2025.
  • $20,000 for an additional digital campaign executed from July 14, 2025, through July 15, 2025.

YachtXotics Enterprises Inc., the sponsoring entity, may hold, purchase, or sell shares of ALBT before, during, or after the promotional campaign period. These financial arrangements and potential trading activity create a direct and material conflict of interest.

All readers and recipients of promotional materials should consider this disclosure carefully. Any content created by Relqo Media LLC regarding ALBT should be viewed as paid advertising, not independent analysis. Relqo Media is financially incentivized to increase investor interest in ALBT, and its communications should be regarded as biased, promotional in nature, and intended to influence investor behavior.

3. INTENDED AUDIENCE

These Communications are directed solely to U.S.-based, self-directed investors who understand the risks of investing in microcap and Nasdaq-listed securities. The content is not intended for children, seniors, retirement accounts, or individuals with limited experience in securities trading. These Communications are not intended to guide investment for long-term portfolio management or financial planning purposes.

4. NO ENDORSEMENT OR VERIFICATION OF COMPANY CLAIMS

Relqo Media LLC does not independently verify, investigate, or audit any statements made by the company being promoted, its officers, its press releases, or any third-party sources. Any claims, projections, customer announcements, or product statements made in connection with ALBT should be assumed to be unverified and potentially inaccurate unless independently confirmed. You should not rely on any statements regarding future performance, partnerships, revenue projections, or corporate plans.

5. MARKET INFLUENCE AND TRADING PATTERN EXPECTATION

Promotional campaigns commonly result in short-lived spikes in stock price and volume, followed by rapid declines. These spikes are typically driven by retail speculation, promotional circulation, and momentary investor interest—not fundamentals. You should expect that:

  • ALBT’s stock may increase temporarily during this promotion,
  • Trading volume may rise sharply, and
  • The price may fall after the campaign ends or selling begins.

These patterns are typical of stock promotions, and you should proceed accordingly.

6. NO RELIANCE – INVESTOR RESPONSIBILITY

The burden of research, investigation, and risk assessment rests solely with you. Relqo Media LLC is not responsible for your investment decisions. You are strongly urged to:

  • Read public filings from the SEC,
  • Consult a licensed financial adviser,
  • Understand risks such as dilution, insider selling, and volatility, and
  • Recognize that speculative stocks often lack financial transparency.

We accept no responsibility for losses incurred due to actions taken based on our Communications.

7. FORWARD-LOOKING STATEMENTS AND SAFE HARBOR

Our materials may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about potential growth, revenue forecasts, market opportunity, strategic partnerships, or technological development. Such statements are speculative and based on assumptions that may never occur. Actual results may differ materially. These statements are made under the safe harbor protections of Sections 27A and 21E of the Securities Acts. Relqo Media disclaims any duty to update them.

8. INFORMATION SOURCING, BIAS, AND ACCURACY

We use publicly available information including company websites, press releases, and promotional materials supplied by paying clients or related parties. We do not verify or validate this data.

Assume all information presented by Relqo Media is:

  • Subjective,
  • Not independently verified,
  • Created to highlight potential upside and omit downsides,
  • Not suitable as the basis for any investment decision.

9. OWNERSHIP AND TRADING CONFLICTS

Relqo Media LLC, its contractors, members, and affiliates may hold or acquire shares in the companies we promote, including ALBT. We may buy or sell such shares without prior notice. These transactions may occur before, during, or after a promotional campaign and may affect market pricing. We are not obligated to update readers on our trading activity or affiliate holdings.

10. MARKETING TOOLS, DATA COLLECTION, AND USER CONSENT

We use a range of outreach and promotional tools, including:

  • Email and newsletter distributions,
  • SMS/MMS text campaigns,
  • Social media posts and influencers,
  • Google and native display ads,
  • Press releases, video marketing, and paid content distribution.

By engaging with our content, you consent to receive ongoing marketing communications. You may unsubscribe, but your data may be retained for audit or compliance purposes. Please refer to our Privacy Policy for further details.

11. ADVERTISING LAW COMPLIANCE

Relqo Media LLC produces promotional content in accordance with the advertising disclosure standards set forth by the Federal Trade Commission (FTC) and the SEC’s interpretations of sponsored investment-related communications.

We make good-faith efforts to disclose all:

  • Compensation arrangements,
  • Conflicts of interest,
  • Risks,
  • Limitations of our role, and
  • The promotional nature of this content.

We do not provide investment recommendations under any regulatory framework including, but not limited to, SEC Regulation Analyst Certification, FINRA Rule 2210, or Regulation Best Interest.

12. NON-U.S. USERS

This material is intended solely for distribution within the United States. If you are accessing this site from outside the U.S., you are responsible for complying with your country’s laws. Relqo Media disclaims liability for access from non-U.S. jurisdictions where investor promotion, marketing, or solicitation of securities is restricted or prohibited.

13. DISCLAIMER OF WARRANTIES AND LIMITATION OF LIABILITY

All content is provided “as-is” and without warranties of any kind, either express or implied. Relqo Media LLC disclaims any and all liability for:

  • Investment losses,
  • Inaccuracies,
  • Technical delays,
  • User misunderstandings,
  • Omissions or errors in content.

Total liability for any claim shall not exceed one hundred dollars ($100).

14. LEGAL GOVERNANCE AND DISPUTE RESOLUTION

All matters arising out of this disclaimer shall be governed by the laws of the State of Wyoming. You agree that any dispute shall be resolved exclusively through binding arbitration under the rules of the American Arbitration Association, to be held in Sheridan County, Wyoming. Class action claims and group arbitration are expressly prohibited.

15. NON-SOLICITATION AND GEOGRAPHIC LIMITATIONS

Nothing in our content constitutes a general solicitation or a personal securities recommendation. If you reside in a jurisdiction where such communications are unlawful, you must exit this site and discontinue engagement with our content.

16. FINAL NOTICE – ACCEPTANCE OF TERMS

We reserve the right to update this Disclaimer at any time without notice. Your continued use of our services or content constitutes acceptance of the most recent version.

If you do not accept all terms of this disclaimer in full, you must:

  • Exit our websites,
  • Unsubscribe from our communications,
  • Discontinue viewing all Relqo Media promotional content.

17. NO RELIANCE

By viewing or engaging with this content, you agree that:

  • You will not rely on any statements made by Relqo Media for investment purposes,
  • You waive any claim that our content was a material factor in your investment decision,
  • You have read, understood, and accepted this disclaimer in full.

© 2024 Relqo Media LLC. All Rights Reserved.

Legal Contact: 📧 support@stockverse.com

Mailing Address: 1309 Coffeen Ave Ste 1200, Sheridan, WY 82801

Affiliate Disclosure: Relqo Media LLC owns and operates Stockverse.com and all affiliated digital properties.